The clinical and financial cost of mental disorders among elderly patients with gastrointestinal malignancies

Jeremy P. Harris¹ | Mehr Kashyap² | Jessica N. Humphreys³ | Erqi L. Pollom² | Daniel T. Chang²

¹Department of Radiation Oncology, University of California, Irvine, Orange, CA, USA
²Department of Radiation Oncology, Stanford University, Stanford, CA, USA
³Division of Palliative Medicine, Department of Medicine, University of California, San Francisco, CA, USA

Correspondence
Jeremy P. Harris, Department of Radiation Oncology, University of California, UC Irvine Health, Chao Family Comprehensive Cancer Center, 101 The City Dr, Bldng 23, Orange, CA 92868, USA.
Email: jeremy.harris@uci.edu

Funding information
There was no supplemental funding utilized to carry out this study.

Abstract
The clinical and financial effects of mental disorders are largely unknown among gastrointestinal (GI) cancer patients. Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, we identified patients whose first cancer was a primary colorectal, pancreatic, gastric, hepatic/biliary, esophageal, or anal cancer as well as those with coexisting depression, anxiety, psychotic, or bipolar disorder. Survival, chemotherapy use, total healthcare expenditures, and patient out-of-pocket expenditures were estimated and compared based on the presence of a mental disorder. We identified 112,283 patients, 23,726 (21%) of whom had a coexisting mental disorder. Median survival for patients without a mental disorder was 52 months (95% CI 50–53 months) and for patients with a mental disorder was 43 months (95% CI 42–44 months) (p < 0.001). Subgroup analysis identified patients with colorectal, gastric, or anal cancer to have a significant association between survival and presence of a mental disorder. Chemotherapy use was lower among patients with a mental disorder within regional colorectal cancer (43% vs. 41%, p = 0.01) or distant colorectal cancer subgroups (71% vs. 63%, p < 0.0001). The mean total healthcare expenditures were higher for patients with a mental disorder in first year following the cancer diagnosis (increase of $16,823, 95% CI $15,777-$18,173), and mean patient out-of-pocket expenses were also higher (increase of $1,926, 95% CI $1753–$2091). There are a substantial number of GI cancer patients who have a coexisting mental disorder, which is associated with inferior survival, higher healthcare expenditures, and greater personal financial burden.

Keywords
colon cancer, financial toxicity, gastrointestinal cancer, mental disorder, SEER-Medicare

1 | INTRODUCTION

Gastrointestinal (GI) malignancies encompass a wide array of cancer subsites, histologies, and prognoses. Uniting these cancers is an increased burden of symptoms related to the diseases and treatments, which in turn results increased rates of hospitalization.¹ In response, oncologists are becoming increasingly aware of the importance of supportive care for managing patients. ASCO recognizes that supportive care measures are paramount to delivering comprehensive oncologic care, and current recommendations advocate for early palliative care interventions for many patients.² Due to the high rate of psychiatric
symptoms for these patients, psycho-oncologic assessments are an important piece of the supportive care measures.

With regards to GI malignancies, it has historically been suggested that mental disorders are less prevalent. However, more recent studies have disputed that claim, finding rates of 18-29% of patients with a pre-existing mental disorder. Thus, developing a better understanding of the impact of having a mental disorder comorbid with a GI cancer is needed.

We set out to determine the clinical and financial implications of having a comorbid mental disorder for elderly patients with GI malignancies in the United States.

2 | METHODS

2.1 | Data source

We employed the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database and identified patients whose first cancer was a primary colorectal, pancreatic, gastric, hepatic/biliary, esophageal, or anal cancer. SEER-Medicare is a large population-based linked-dataset maintained by the National Cancer Institute. It details inpatient and outpatient medical claims from Medicare beneficiaries who have cancer and are included in the SEER database, which is a registry that covers approximately 34% of the U.S. population.

2.2 | Patient selection

The cohort included patients diagnosed 2004-2013 who were at least 65 years old with Medicare Part A and B enrollment without HMO coverage starting 12 months prior to cancer diagnosis to ensure completeness of claims data. We excluded patients with missing or incomplete age, stage, date of diagnosis, or follow up/death information. Censoring occurred at the end of December 2014 or when Medicare coverage was lost.

2.3 | Mental disorder identification

Medicare billing claims were used to identify patients with mental disorders. We included patients with depression disorders (ICD9 diagnosis codes 296.2-296.36, 300.4, 311), anxiety disorders (ICD9 diagnosis codes 293.84, 300-300.09, 300.10, 300.2-300.3, 300.5, 308-308.9, 309.81, 313.0), psychotic disorders (ICD9 diagnosis codes 293.81-293.82, 295-295.95, 297-297.98), and bipolar disorders (ICD9 diagnosis codes 296.0-296.16, 296.4-296.99). A coexisting mental disorder was defined as a condition identified in any billing claim 12 months prior to 6 months following the GI cancer diagnosis. To reduce immortal time bias, only patients living at least 6 months after cancer diagnosis were included in this study.

2.4 | Demographic and clinical characteristics

Using data from the SEER registry, we categorized the following demographics: age, sex, race, Hispanic ethnicity, marital status, and area income. We determined whether patients had dual Medicaid, which can identify patients who are considered low-income. Clinical characteristics identified from SEER data were cancer stage (grouped by local, regional, or distant according to SEER summary staging), and disease subsite. A Charlson comorbidity index modified for cancer patients was used as a proxy for overall comorbidity burden and was determined through inpatient and outpatient medical claims.

2.5 | Endpoint identification

Overall survival (OS) was the time from diagnosis to death, with censoring occurring at the end of December 2014. Cause of death data were used to determine cancer-specific mortality (CSM). Total inpatient and outpatient healthcare expenditures were estimated from a summation of a patient’s Medicare Part A and Part B reimbursements from Medicare and third-party payers and patient payments. Cost estimates included those from all hospital and outpatient associated claims. Patient out-of-pocket expenses were the total deductible and coinsurance costs for Medicare Part A and Part B claims. Prices were converted to 2019 dollars by using the Consumer Price Index. Use of chemotherapy or radiation therapy was identified within 6 months of cancer diagnosis through Medicare claims and included intravenously and orally administered drugs. Site-specific surgical intervention was classified by local excision/ablation or surgical resection according to SEER classifications.

2.6 | Statistical Analysis

Clinical and demographic characteristics were compared between patients with or without a coexisting mental disorder using chi-squared tests. Survival was estimated with Kaplan-Meier methods, and between group comparisons were made with log-rank testing. Between group survival comparisons were also made using propensity score matched cohorts to control for confounding variables. Cumulative incidence estimates were used to determine CSM rates with non-cancer
results defined as competing events, and between group comparisons were made with Gray’s tests. Propensity scores were determined from a logistic regression for the odds of having a mental disorder using age, sex, race, ethnicity, marital status, area income, dual Medicaid status, cancer stage, Charlson comorbidity index, and disease subsite. 1:1 matching was done with a nearest-neighbor technique with a maximum caliper of 0.05 times the standard deviation of the logit of the propensity score.\(^{15,16}\) Balance was assessed with a 10% maximum standardized difference.\(^{17}\)

Individual subgroup analysis of mortality was performed with multivariable proportional hazards models. Adjustments were made for age, sex, race, ethnicity, marital status, area income, dual Medicaid status, cancer stage, Charlson comorbidity index, and disease subsite. The proportional hazards assumption was evaluated using log-log plots and Schoenfeld residuals.

Propensity score matching was also done for individual subgroups by cancer subsite and stage. Within these subgroups, OS and the use of chemotherapy was compared based on the presence of a mental disorder using log-rank and McNemar’s tests, respectively.

The unadjusted per-year total healthcare spending was compared between groups with Mann-Whitney U testing. Patients needed Medicare claims data for each year to be included in that year’s cost assessment. Adjusted annual estimates for total and patient out-of-pocket expenditures were made using a two-part model because the cost data was right skewed and there were a portion of zero values.\(^{18}\) The first part was a multivariable logistic regression for having any non-zero costs. The second part was a generalized linear model for the mean cost conditional on there being greater than zero cost and using a gamma distribution with a log link.\(^{19}\) Differences in mean total and patient out-of-pocket costs were determined based on mental disorder status. Bootstrapping methods were used to estimate confidence intervals in differences.

Statistical significance was set at 0.05, and all tests were two-tailed. Data analysis and statistical testing was performed using R (version 3.5, R Foundation for Statistical Computing, Vienna, Austria).

3 | RESULTS

We identified 112,283 patients who met inclusion criteria (Figure S1). Represented cancer subsites were colorectal \((n = 60283)\), pancreatic \((n = 7977)\), gastric \((n = 7204)\), hepatic/biliary \((n = 7513)\), esophageal \((n = 4158)\), and anal cancer \((n = 1422)\). There were 23,726 patients \((21\%)\) with a coexisting mental disorder, composed of 16,138 \((21\%)\) of the colorectal cancer cohort, 2,401 \((23\%)\) of the pancreatic cancer cohort, 1,792 \((20\%)\) of the gastric cancer cohort, 1,891 \((20\%)\) of the hepatic/biliary cancer cohort, 1,001 \((19\%)\) of the esophageal cancer cohort, and 503 \((26\%)\) of the anal cancer cohort (Table 1). There were 15,091 patients \((13\%)\) with coexisting depression, 11,180 patients \((10\%)\) with coexisting anxiety, 3594 patients \((3\%)\) with coexisting psychotic, and 1052 patients \((0.9\%)\) with coexisting bipolar disorders (Tables S1-S4).

After propensity score-based matching, median survival for patients without a mental disorder was 52 months \((95\%\ CI\ 50–53\ months)\) and for patients with a mental disorder was 43 months \((95\%\ CI\ 42–44\ months, p < 0.001, Figure 1)\.

Subgroup analysis by disease site was done with propensity score-based matching and demonstrated a statistically significant difference in survival according to mental disorder status for patients with colorectal (median OS 72 months \([95\%\ CI\ 70–74\ months]\) vs 59 months \([95\%\ CI\ 57–61\ months]\), \(p < 0.0001)\) and anal cancer (median OS 74 months \([95\%\ CI\ 61–85\ months]\) vs 55 months \([95\%\ CI\ 46–65\ months]\), \(p = 0.045)\). Results were similar with unmatched, raw data (Figure S2).

On multivariable analysis, having a mental disorder was associated with inferior overall survival \((HR 1.16, 95\%\ CI 1.14–1.18)\). Individual subgroup analysis found a similar relationship for patients with colorectal \((HR 1.25, 95\%\ CI 1.22–1.28)\), gastric \((HR 1.07, 95\%\ CI 1.00–1.15)\), and anal cancer \((HR 1.23, 95\%\ CI 1.06–1.43)\) (Figure 2). According to disease stage, the biggest association between mental disorder and survival was for local disease \((HR 1.23, 95\%\ CI 1.19–1.27)\), followed by regional disease \((HR 1.16, 95\%\ CI 1.12–1.19)\), followed by distant disease \((HR 1.06, 95\%\ CI 1.02–1.11)\).

Propensity score-based matching was done on individual stage subgroups for patients with colorectal, gastric, and anal cancer, for whom survival differed based on mental disorder status. A significant decrease in OS was associated with having a mental disorder for subgroups of patients with local or regional colorectal cancer or regional gastric cancer only (Figure S3).

After propensity score-based matching, 5-year CSM was 30% for patients without a mental disorder and 31% for those with a mental disorder \((p = 0.03)\). Subgroup analysis by disease site was done with propensity score-based matching and demonstrated a statistically significant increase in CSM for patients with a mental disorder and colorectal cancer \((5-year\ incidence\ of\ 20%\ vs\ 21%, p < 0.0001)\), but a decrease in CSM for patients with pancreatic cancer \((5-year\ incidence\ of\ 80%\ vs\ 77%, p = 0.03)\) (Figure S4). Directional patterns were similar with unmatched, raw data, but there was also a decrease in CSM for patients with a mental disorder and gastric cancer \((5-year\ incidence\ of\ 37%\ vs\ 32%, p = 0.003)\) (Figure S5).

Chemotherapy use differed for patients with regional colorectal cancer \((43%\ vs\ 41%\ with\ a\ mental\ disorder, p = 0.01)\), distant colorectal cancer \((71%\ vs\ 63%\ with\ a\ mental\ disorder, p = 0.01)\), and distant colorectal cancer \((51%\ vs\ 38%\ with\ a\ mental\ disorder, p = 0.01)\).
| Demographic and clinical characteristics according to coexisting mental disorder status. |
|-----------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| **Disease subsite**                                 | **No mental disorder** | **Diagnosed mental disorder** | **p value** |
| Colorectal                                           | 60283            | 16138            | <0.0001        |
| Pancreatic                                           | 7977             | 2401             | 10%            |
| Gastric                                              | 7204             | 1792             | 8%             |
| Hepatic/biliary                                      | 7513             | 1891             | 8%             |
| Esophageal                                           | 4158             | 1001             | 4%             |
| Anal                                                 | 1422             | 503              | 2%             |
| **Age group**                                        | **n**            | **%**            | **n**            | **%**            | **p value** |
| 65–74                                                | 39687            | 45%              | 10105            | 43%              | <0.0001     |
| 75–84                                                | 36474            | 41%              | 9686             | 41%              |            |
| ≥85                                                  | 12396            | 14%              | 3935             | 17%              |            |
| **Sex**                                              | **Male**         | **Female**       | **n**            | **%**            | **n**            | **%**            | **p value** |
| Male                                                 | 46484            | 52%              | 8767             | 37%              | <0.0001     |
| Female                                               | 42073            | 48%              | 14959            | 63%              |            |
| **Race**                                             | **White**        | **Black**        | **n**            | **%**            | **n**            | **%**            | **p value** |
| White                                                | 72890            | 82%              | 20873            | 88%              | <0.0001     |
| Black                                                | 8096             | 9%               | 1778             | 7%               |            |
| Asian/Pacific Islander                               | 6882             | 8%               | 926              | 4%               |            |
| North American Native                                | 374              | 0%               | 82               | 0%               |            |
| Unknown                                              | 315              | 0%               | 67               | 0%               |            |
| **Ethnicity**                                        | **Non-Hispanic** | **Hispanic**     | **n**            | **%**            | **n**            | **%**            |
| Non-Hispanic                                         | 82625            | 93%              | 22140            | 93%              | 0.95        |
| Hispanic                                             | 5932             | 7%               | 1586             | 7%               |            |
| **Marital status**                                   | **Married/domestic partner** | **Widowed** | **Single** | **Separated/divorced** | **Unknown** | **n**            | **%**            | **n**            | **%**            | **p value** |
| Married/domestic partner                             | 48436            | 55%              | 10264            | 43%              | <0.0001     |
| Widowed                                              | 22854            | 26%              | 7731             | 33%              |            |
| Single                                               | 7184             | 8%               | 2280             | 10%              |            |
| Separated/divorced                                   | 6427             | 7%               | 2357             | 10%              |            |
| Unknown                                              | 3656             | 4%               | 1094             | 5%               |            |
| **Area income**                                      | **Highest**     | **Third**        | **Second**       | **Lowest**       | **Unknown** |
| Highest                                              | 21408            | 24%              | 5265             | 22%              | <0.0001     |
| Third                                                | 20451            | 23%              | 5408             | 23%              |            |
| Second                                               | 19730            | 22%              | 5612             | 24%              |            |
| Lowest                                               | 18752            | 21%              | 5755             | 24%              |            |
| Unknown                                              | 8216             | 9%               | 1686             | 7%               |            |
| **Dual Medicaid status**                             | **No**           | **Yes**          | **n**            | **%**            | **n**            | **%**            | **p value** |
| No                                                   | 70008            | 79%              | 16274            | 69%              | <0.0001     |
| Yes                                                  | 18549            | 21%              | 7452             | 31%              |            |
| **Charlson comorbidity index**                       | **n**            | **%**            | **n**            | **%**            | **p value** |
| 0                                                    | 41169            | 46%              | 8229             | 35%              | <0.0001     |
| 1                                                    | 22492            | 25%              | 6037             | 25%              |            |
| 2                                                    | 11973            | 14%              | 3891             | 16%              |            |
| ≥3                                                   | 12923            | 15%              | 5569             | 23%              |            |

(Continues)
mental disorder, $p < 0.0001$), regional pancreatic cancer (71% vs 67% with a mental disorder, $p = 0.03$), regional esophageal cancer (73% vs 80% with a mental disorder, $p = 0.04$) (Table S5). Radiation
therapy was more likely to be employed for patients with a mental disorder and any stage colorectal, distant pancreatic, local gastric, distant gastric, local hepatic/biliary, regional hepatic/biliary, and local anal cancer (Table S6). Patients with mental disorders were also less likely to undergo local excision/ablation for local colorectal cancer (14% vs 12%, \( p = 0.0006 \)) (Table S7). Finally, having a mental disorder made it less likely for patients to undergo local excision/ablation for local gastric cancer (16% vs 15%), but more likely to have a larger surgical resection (53% vs 60%, \( p = 0.02 \)).

The median total inpatient and outpatient unadjusted healthcare expenditures were higher for patients without and with a mental disorder in each year studied (Figure 3). Two-part models for the mean total healthcare expenditures determined that costs were higher for patients with a mental disorder in the year prior to (increase of $8873, 95% CI $8295-$9414), first year following (increase of $16,823, 95% CI $15,777-$18,173), and second year following the cancer diagnosis (increase of $837, 95% CI $434-$1206) (Table 2). There were not significant differences in the third to fifth year following the cancer diagnosis. Similarly, mean patient

**FIGURE 2** Association between mental disorder status and overall survival by individual subgroup. Each cohort represents findings from individual subgroup multivariable analysis.
out-of-pocket expenses were higher for patients with a mental disorder in the year prior to (increase of $1085, 95% CI $1035-$1132), first year following (increase of $1926, 95% CI $1753-$2091), and second year following the cancer diagnosis (increase of $109, 95% CI $62–$161).

4 | DISCUSSION

In this study of an elderly cohort, 21% of patients were identified with a coexisting mental disorder, which was associated with a decrease in median OS from 52 months to 43 months and slight increase in 5-year CSM from 30% to 31%. This association was most dramatic for patients with local disease at presentation, as well as the subgroups with colorectal or anal cancer. In addition, having a mental disorder was associated with a decreased chance of receiving chemotherapy for regional or distant stage colorectal cancer, decreased probability of having a local excision/ablation for local colorectal cancer, and increased probability of receiving radiation therapy for many groups. Finally, total inpatient and outpatient healthcare expenditures were an average of $16,000 higher for patients with mental disorders in the first year following a cancer diagnosis, which consisted of an increase of $2,000 in patient out-of-pocket costs.

Our finding of the substantial health outcome disparity with having a mental disorder is consistent with prior studies...
of patients with GI malignancies. Some proposed explanations have included that in general, patients with psychiatric illnesses can be more likely to have advanced cancer at the time of presentation, less likely to undergo surgery, and more likely to have fewer cycles of chemotherapy. In the United States, studies have demonstrated that patients with colon cancer are less likely to receive definitive treatment, and those with rectal cancer are less likely to undergo a sphincter sparing surgery when they have a comorbid mental disorder. Similarly, in the current study, we found that certain subgroups with colorectal or pancreatic cancer were less likely to undergo chemotherapy when they had a coexisting mental disorder, and those with local colorectal cancer were less likely to undergo local excision/ablation. Interestingly, patients with a mental disorder were in general more likely to receive radiation therapy. However, the intent of radiation therapy was not known in this study, which could make interpretation more challenging. For example, while the increased use of radiation therapy for patients with distant stage colorectal cancer may be consistent with attentiveness to symptomatic control, the increased use of radiation therapy for those with local or regional colorectal cancer could imply the lack of timely definitive treatment, more aggressive tumors with higher probability of progression, or even residual bias with more advanced cancers among patients with mental disorders. We would also point out that the large differences in OS were not fully explained by CSM, implying that comorbid factors other than CSM are challenging to navigate. Again, these explanations are consistent with our findings of inferior OS and CSM among some subgroups in the presence of a comorbid mental disorder. Lastly, there could be a potential biological explanation that mental disorders increase the body's stress response, which in turn could result in worse clinical outcomes.

Mental disorder management should be considered critical not only because of the therapeutic and oncologic outcome discrepancies identified in this study, but also because non-cancer mortality rates were higher for these patients. In response, there has been interest in determining how to better manage the psychiatric symptoms for cancer patients. Psychotherapy and counseling have shown to improve depression symptoms and quality of life for cancer patients. It is also plausible that the resulting improved psychiatric symptom burden could decrease the body's stress response and result in improved survival. Medications have similarly shown a benefit, with one retrospective study showing an improvement in lung cancer-specific survival and suggesting a biological role for certain tricyclic antidepressants or norepinephrine and dopamine reuptake inhibitors. Furthermore, this is an area where patients sometimes turn to complementary and alternative medicine, though the quality of supporting data is generally low.

Additionally, for patients with mental disorders there have been investigations in improving cancer detection to reduce the stage distribution disparity. In the current study, patients with a mental disorder were slightly more likely to be diagnosed with regional disease. In one recent meta-analysis, identified themes included implementing screening templates, staff education/training, automated physician prompting, and integration of psychiatric with physical healthcare.

### Table 2

| Diagnosis | Total healthcare expenditures | Patient out-of-pocket expenditures |
|-----------|-------------------------------|-----------------------------------|
| | Mental disorder absent | Mental disorder present | Change (increase or decrease) with a mental disorder | 95% Confidence Interval ($) | Mental disorder absent | Mental disorder present | Change (increase or decrease) with a mental disorder | 95% Confidence Interval ($) |
| Year prior to diagnosis | $10,307 | $19,181 | $8873 | $(8295 to $9414) | $1517 | $2,602 | $1,085 | $(1035 to $1132) |
| Year 1 | $70,157 | $86,980 | $16,823 | $(15,777 to $18,173) | $9009 | $10,936 | $1,926 | $(1753 to $2091) |
| Year 2 | $10,669 | $11,507 | $837 | $(434 to $1,206) | $1679 | $1,788 | $109 | $(62 to $161) |
| Year 3 | $4,811 | $4,937 | $127 | (-$91 to $355) | $759 | $757 | -$2 | (-$36 to $31) |
| Year 4 | $2,495 | $2,328 | -$167 | (-$310 to -$34) | $390 | $358 | -$31 | (-$51 to -$9) |
| Year 5 | $1,316 | $1,097 | -$219 | (-$289 to -$121) | $202 | $166 | -$36 | (-$45 to -$24) |
While these methods generally show some amount of success, there remain challenges from a resource, patient-engagement, practitioner education/training, and workload standpoint. The Centers for Disease Control and Prevention (CDC) has recognized this problem and created the free, online Provider Education for Mental Health Care of Cancer Survivors Training, and through the National Comprehensive Cancer Control Program the CDC is funding projects addressing psychiatric symptoms among cancer survivors. 

With regards to the higher healthcare expenditures for patients with mental disorders that were identified in this study, these patients are more likely to have higher rates of healthcare utilization, and consequently, experience significant personal financial hardship due to incurred costs. Cancer patients with depression, for example, have more emergency department visits, overnight hospital admissions, 30-day readmissions, and non-mental health provider visits. This increase in utilization translates into higher total healthcare costs, including inpatient, outpatient, prescription drug, and long-term care costs. Of note, our findings showed that these increased costs were despite a lower utilization of chemotherapy or surgical intervention for some patients with colorectal and pancreatic cancer. However, most subgroups in the current study were more likely to receive radiation therapy, which could also be related to the increased costs. Higher costs of care are particularly unfavorable since cancer patients, in general, experience more financial hardship, such as difficulty paying medical bills and forgoing care due to cost compared to those without cancer.

Providing mental health services could mitigate the financial burden associated with having a mental disorder, though evidence is currently limited and mixed. In one recent study, cancer patients with depression often had significantly lower annual healthcare costs when they were seen by mental health providers. Similarly, a Canadian prospective study of patients with early stage breast cancer found that patients who participated in cognitive behavioral psychosocial meetings had lower healthcare expenditures. Nevertheless, there is also contrary evidence that indicates treatments such as psychotherapy and antidepressants may not significantly impact long-term healthcare expenditures in cancer patients with depression. Together, these studies demonstrate a need to better understand which patients will benefit most from psychiatric interventions and what services are most effective.

Limitations of the current study include that it is retrospective and naturally incurs selection bias. In addition, despite propensity-score matching and multivariable economic modeling, there may be important unmeasured confounders that could bias the study. We utilized billing claims from the Medicare insurance program, which may underrepresent the true rate of mental disorders among cancer patients. Cause of death data in the registry may not be accurate, which can bias CSM analyses. Furthermore, these billing claims do not contain data on the cost or clinical effect of prescription or over-the-counter drug use, and additional studies of psychiatric medications especially are necessary to determine mental health treatment effects. In addition, given the wide range of cancer therapy including specific surgical procedures and type of radiation therapy and other ancillary care associated with these treatments, we were unable to further characterize sources of increased costs for patients with disorders. Finally, our cohort represented an elderly group of mostly white patients with GI cancers and may not be generalizable to younger or more diverse groups of patients.

5 CONCLUSIONS

In summary, GI cancer patients with comorbid mental disorders are more likely to have compromised overall and cancer-specific survival outcomes, higher healthcare expenditures, and greater personal financial burden. Patients with regional or distant colorectal cancer were less likely to receive chemotherapy, those with local colorectal cancer were less likely to undergo local excision/ABLATION, and many groups were more likely to receive radiation therapy. Understanding the mental health of one’s patient is crucial not only because of the significant rate and detrimental effects of having a mental disorder, but also because a number of therapeutic options are available. This study further highlights the importance of efforts such as the free mental health screening training for physicians made available by the CDC. Lastly, reducing personal costs remains an understudied, unmet need in health services research.

CONFLICTS OF INTEREST

No authors have any conflicts of interest to report for this work.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the National Cancer Institute. Restrictions apply to the availability of these data, which were used under license for this study. Data are available at https://healthcaredelivery.cancer.gov/seermedicare/ with the permission of the National Cancer Institute.

ORCID

Jeremy P. Harris https://orcid.org/0000-0001-7603-0263
Mehr Kashyap https://orcid.org/0000-0002-7336-1056
Daniel T. Chang https://orcid.org/0000-0003-2760-1554

REFERENCES

1. Manzano J-G, Luo R, Elting LS, et al. Patterns and predictors of unplanned hospitalization in a population-based cohort of elderly patients with GI cancer. J Clin Oncol. 2014;32:3527–3533.
2. Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: American society of clinical oncology
clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:96–112.

3. Massic MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004;57–71.

4. Wiegard NE, Hart KD, Herzig DO, et al. Psychiatric Illness is a Disparity in the Surgical Management of Rectal Cancer. Ann Surg Oncol. 2015;22(Suppl 3):S573–S579.

5. Ho VP, Steinhaug E, Angell K, et al. Psychiatric disease in surgically treated colorectal cancer patients. J Surg Res. 2018;223:8–15.

6. Baillargeon J, Kuo Y-F, Lin Y-L, et al. Effect of mental disorders on diagnosis, treatment, and survival of older adults with colon cancer (Report). J Am Geriatr Soc. 2011;59:1268–1273.

7. Song H, Zhu J, Lu D, et al. Psychiatric morbidity and its impact on surgical outcomes for esophageal and gastric cancer patients: A nationwide cohort study. Oncotarget. 2017;8:81305–81314.

8. Brief Description of SEER-Medicare Database [Internet]. 2019. [cited 2019 Jul 17] Available from: https://healthcaredelivery.cancer.gov/seermedicare/overview/

9. About the SEER Program [Internet]. SEER [cited 2019 Jul 17] 2019. Available from: https://seer.cancer.gov/about/index.html

10. Young J, Roffiers S, Ries L, eds. In: SEER Summary Staging Manual - 2000: Codes and Coding Instructions. MD, Bethesda: National Cancer Institute, 2001.

11. Klubunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data [Internet]. J Clin Epidemiol. 2000;53:1258–1267. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11146273

12. Comorbidity SAS Macro (2014 version) [Internet]. 2019. [cited 2019 Jul 17] Available from: https://healthcaredelivery.cancer.gov/seermedicare/considerations/macro-2014.html

13. U.S. Bureau of Labor Statistics [Internet]. 2019. [cited 2019 Oct 15] Available from: https://www.bls.gov/cpi/

14. Procedure Codes for SEER-Medicare Analyses [Internet]. 2019. [cited 2019 Dec 2] Available from: https://healthcaredelivery.cancer.gov/seermedicare/considerations/procedure_codes.html

15. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150–161.

16. Ho DE, Imai K, King G, et al. Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference [Internet]. Polit Anal. 2007;15:199–236. [cited 2019 Oct 16] Available from: https://www.cambridge.org/core/journals/political-analysis/article/matching-as-nonparametric-preprocessing-for-reducing-model-dependence-in-parametric-causal-inference/4D7E6D07C9727F5A604E5C9FCCA2DD21#. 

17. Austin PC. Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score [Internet]. Pharmacoepidemiol Drug Saf 2008;17:1218–1225.

18. Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs [Internet]. Ann Rev Pub Health 1999;20:125–144. [cited 2019 Oct 16] Available from: https://www.annualreviews.org/doi/10.1146/annurev.pubhealth.20.1.125

19. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24:465–488.

20. Kisely S, Crowe E, Lawrence D. Cancer-related mortality in people with mental illness. JAMA Psychiatry. 2013;70:209–217.

21. Kaerlev L, Iachina M, Trosko O, et al. Colon cancer patients with a serious psychiatric disorder present with a more advanced cancer stage and receive less adjuvant chemotherapy - A Nationwide Danish Cohort Study. BMC Cancer. 2018;18:1050.

22. Zhu J, Fang F, Sjölander A, et al. First-onset mental disorders after cancer diagnosis and cancer-specific mortality: a nationwide cohort study. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:1964–1969.

23. Koroukian SM, Sajatovic M. Increased cancer-specific mortality in individuals developing mental disorders after cancer diagnosis: biomedical factors versus psychosocial support. Ann Transl Med. 2017;5:432.

24. Strawbridge R, Young AH, Cleare AJ. Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatr Dis Treat. 2017;13:1245–1262.

25. Chida Y, Hamer M, Wardle J, et al. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol. 2008;5:466–475.

26. Meulen IC, May AM, Ros WJG, et al. One-year effect of a nurse-led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist. 2013;18:336–344.

27. van der Meulen IC, May AM, de Leeuw JRI, et al. Long-term effect of a nurse-led psychosocial intervention on health-related quality of life in patients with head and neck cancer: a randomised controlled trial. Br J Cancer. 2014;110:593–601.

28. Peoples AR, Garland SN, Pigeon WR, et al. Cognitive behavioral therapy for insomnia reduces depression in cancer survivors. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med. 2019;15:129–137.

29. Spiegel D. Mind matters in cancer survival. Psychooncology. 2012;21:588–593.

30. Zingone A, Brown D, Bowman ED, et al. Relationship between anti-depressant use and lung cancer survival. Cancer Treat Res Commun. 2017;10:33–39.

31. Felbel S, Meerpolh JJ, Monsef I, et al. Yoga in addition to standard care for patients with haematological malignancies. Cochrane Database Syst Rev. 2014; CD010146.

32. Salhofer I, Will A, Monsef I, et al. Meditation for adults with haematological malignancies. Cochrane Database Syst Rev 2016;2:CD011157.

33. Lamontagne-Godwin F, Burgess C, Clement S, et al. Interventions to increase access to or uptake of physical health screening in people with severe mental illness: a realist review. BMJ Open. 2018;8:e019412.

34. Ekwueme DU, Lunsford NB, Khushalani JS, et al. Public health initiatives when using many-to-one matching on the propensity-score in patients with head and neck cancer. Psychooncology. 2018;27:1035–1040.

35. Zwahlen M, Murer HP, Egger M, et al. Systematic review of health screening and health service utilization in patients with cancer. Med Care. 2004;42:512–521.

36. Khushalani JS, Qin J, Cyrus J, et al. Systematic review of health screening and health service utilization in patients with cancer. Med Care. 2018;56:505–517.

37. Zheng Z, Jemal A, Han X, et al. Medical financial hardship among cancer survivors in the United States. Cancer. 2019;125:1737–1747.

38. Mauvais-BT, BC, Bos T, Irwin SA. Medical health treatment dose and annual healthcare costs in patients with cancer and major depressive disorder. Health Psychol Off J Div Health Psychol Am Psychol Assoc. 2018;37:1035–1040.

39. Simpson JS, Carlson LE, Trew ME. Effect of group therapy for breast cancer on healthcare utilization. Cancer Pract. 2001;9:19–26.
41. Alwhaibi M, Sambamoorthi U, Madhavan S, et al. Depression treatment and healthcare expenditures among elderly Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or prostate cancer. *Psychooncology*. 2017;26:2215–2223.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.